This article was originally published in The Gray Sheet
Latex condoms are "highly effective for preventing HIV infection and other [sexually transmitted diseases] when used consistently and correctly," the Centers for Disease Control and Prevention concludes in the Aug. 6 Morbidity and Mortality Weekly Report. CDC cites two studies of condom use among HIV serodiscordant heterosexual couples. In one study, "none of 123 partners who used condoms consistently seroconverted," while 12 (10%) of 122 seronegative partners who use condoms inconsistently seroconverted. In the second study, three (2%) of 171 consistent condom users seroconverted, compared with eight (15%) of 55 inconsistent condom users. In addition, "three prospective studies in developed countries indicated that condoms are unlikely to break or slip during proper use," CDC says.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.